according to Liverpool University researchers analysed prices for 20 generic cancer drugs – which means they can be made cheaply by any manufacturer – between 2011 and 2016.
He said: “Exciting new cancer drugs are taking too long to reach the people who urgently need them.
“Some firms take over the supply of generic cancer medicines and then raise the price progressively.
Some of these drugs cost just a few pence to make.
6 Drugs firms have been exposed as hiking up prices of lifesaving cancer drugs for the NHSExperts said makers should be probed over the hikes – which rip off the NHS and lead to cancer victims losing out.
as mentioned in “We hope that by using these computational approaches to understanding cancer cell systems, we’ve widened the field for finding the new desperately needed cancer drugs,” said Dr Módos.
Could the proteins that neighbour cancer-related proteins at the centre of cellular signalling networks, not directly involved in carcinogenesis themselves, be useful drug targets themselves?
This could be overcome by targeting proteins that have a specific, directed influence on the first neighbour proteins, identified by analysing the interaction networks.
But sometimes, environmental factors cause mutations that change how some of these proteins work, rewiring the network into a cancer cell.
Others have seen how cancer-related proteins hold these central positions in networks.
Europe faces steep price increases for some old cancer drugs
as mentioned in Industry critics argue some companies take over supply of certain generic drugs and then raise prices progressively to maximize profits.
“Prices aren’t as high as in the US but these are generic drugs and, as such, they should be available at close to the cost of production.”
The European Consumer Organisation BEUC, meanwhile, wrote to European Commissioner for Competition Margrethe Vestager in October asking her investigate potential cases of unfair generic drug prices across the European Union.
“It seems to be happening quite frequently across Europe,” said Andrew Hill of the University of Liverpool, who presented the data with a colleague from the London School of Hygiene and Tropical Medicine at the European Cancer Congress in Amsterdam.
LONDON: European prices for some off-patent Cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent, according to data presented at a medical conference on Saturday.
about the details read more from here
This content may collect you by Sydney Connor